• Region: Europe
  • Sector: Healthcare
  • Investment Year: 2015
  • Transaction Value: €475m

In September 2015, BCEC IX acquired Pharmathen from the founding family. Pharmathen is a leading European pharmaceutical company focused upon developing, manufacturing and out-licensing complex generic drugs.

Pharmathen has a B2B Business Model and focuses on: out-licensing to over 265 customers in over 85 countries; Manufacturing Supply Agreements with minimum 5-year contracts; and a portfolio of 110 own-developed drugs. Additionally, Pharmathen undertakes R&D in Greece with 2 facilities, along with manufacturing at 2 facilities, also in Greece.

The company is headquartered in Amsterdam.

For more information on Pharmathen, please watch the video here.

Company News

03 June 2015

BC Partners acquires Pharmathen

Funds advised by BC Partners (“BC Partners”), a leading international private equity firm, have reached an agreement to acquire a majority stake in Pharmathen S.A (“Pharmathen” or “the Company”), a leading European pharmaceutical company. BC Partners will

Read More

Team Involved